MDT Q4 earnings beat and acceleration

Medtronic (MDT) reported Q4 2026 earnings on Wednesday, beating revenue estimates with $9.81 billion and EPS of $1.47, up 12% year-over-year. The medical device giant's share price surged 5.7% to $77.95, driven by strong earnings growth and a full-year sales increase of 8.5%.

The healthcare sector and specifically medical device stocks are beneficiaries of this narrative, as Medtronic's robust performance signals a resilient demand for medical technologies. This could lead to a valuation repricing of similar companies, with investors seeking exposure to the sector's growth potential.

Investors should watch for MDT's Q1 2027 earnings report, scheduled for August 24, to confirm the sustainability of this earnings acceleration. Additionally, they should monitor the progress of Medtronic's strategic initiatives, such as its integration of the recently acquired Mazor Robotics, which could further boost growth.